Therapeutic Approach

Category: Uncategorized

Ritter Pharmaceuticals, Inc.’s Board Approves 1-for-10 Reverse Stock Split

Los Angeles, California, March 1, 2018 – Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a leading developer of novel therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases with an initial focus on establishing the first FDA-approved treatment for lactose intolerance, today announced that its Board of Directors (the “Board”) […]

Leave Your Comments »

Featuring Recent Posts WordPress Widget development by YD